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Abstract
Gastroesophageal reflux disease (GERD) is a chronic condition in which patients 
suffer troublesome symptoms and/or complications as the reflux of stomach 
contents occurs. GERD is a common disease worldwide with the range of estimated 
prevalence 18.1–27.8% in North America, 8.8–25.9% in Europe, 2.5–7.8% in East 
Asia, 8.7–33.1% in the Middle East, 11.6% in Australia and 23.0% in South America. 
It causes significant morbidity, considerable decrease of quality of life and high 
costs of exams and treatment derived from repeated visit doctor. The patients with 
GERD suffer from typical symptoms such as heartburn and regurgitation, as well 
as other atypical symptoms including chest pain, cough, asthma, and hoarseness. 
With the usage of pump inhibitors (PPIs) in clinic, a dramatic improvement in 
symptom resolution and life quality, as well as in mucosal healing is expected. 
However, the treatment of GERD fails in a proportion of patients despite the 
high efficacy of PPIs. This situation is getting more and more common in clinical 
practices. In this chapter, we will discuss about this difficult situation, emphasizing 
diagnosis and treatment, combined with suggested management of these patients.
Keywords: gastroesophageal reflux disease (GERD), refractory proton pump 
inhibitor (PPI) symptoms, high-resolution manometry (HRM), impedance-pH 
monitoring, refractory reflux symptoms
1. Introduction
Gastroesophageal reflux disease (GERD) is a chronic condition in which patients 
suffer troublesome symptoms and/or complications as the reflux of stomach con-
tents occurs. GERD is a common disease worldwide with the range of an estimated 
prevalence of 18.1–27.8% in North America, 8.8–25.9% in Europe, 2.5–7.8% in East 
Asia, 8.7–33.1% in the Middle East, 11.6% in Australia, and 23.0% in South America 
[1]. It causes significant morbidity, considerable decrease of quality of life, and high 
costs of exams and treatment derived from repeated visits to the doctor.
The patients with GERD suffer from typical symptoms, such as heartburn and 
regurgitation, as well as other atypical symptoms including chest pain, cough, 
asthma, and hoarseness. With the usage of proton pump inhibitors (PPIs) in the 
clinic, a dramatic improvement in symptom resolution and life quality, as well as in 
mucosal healing, is expected.
However, the treatment of GERD fails in a proportion of patients despite the 
high efficacy of PPIs. This situation is referred as to refractory GERD symptoms. 
What is worse, it is getting more and more common in clinical practices. In this 
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chapter, we will discuss about this difficult situation, emphasizing on diagnosis and 
treatment, combined with suggested management of these patients.
2. Definition of refractory GERD symptom
The definition of “refractory GERD” has traditionally been described as a group 
of varying symptom presentations related to GERD, which persists even though 
the patients accepted the standard daily PPI therapy for at least 12 weeks. Some 
researchers referred to a failure to achieve satisfactory symptomatic response, for 
example, less than 50% improvement of relief of symptoms and life quality, to 
once-daily PPI to be classified as “refractory GERD” or “refractory reflux symp-
toms” [2]. The continued symptoms must be to a degree that impairs quality of life, 
and symptoms must be “reflux-related,” which are supposed to be influenced by 
sex, age, ethnicity, social status, comorbidity, and cultural background. However, 
there is a controversy of the PPI dose for the definition of “refractory GERD.” 
Some investigators prefer that inadequate response to twice-daily PPI treatment as 
refractory disease [3]. Moreover, the patient’s remaining symptoms are subjective 
to and dependent on the patient’s expectations of the therapy. It needs more clini-
cal practice and further researches to supplement the definition in the future.
3. Causes of refractory GERD symptom
There are some underlying causes of refractory GERD. Firstly, poor compliance 
and adherence should be excluded before further evaluation is pursued. There are 
some key points of medication administration for patients, such as taking PPIs at the 
optimal 30–60 minutes prior to meal; avoiding discontinued PPIs without doctors’ 
instruction even though the symptoms are relieved; receiving enough information 
about PPIs therapy. These points are initial important considerations for resolving 
the refractory GERD. Then, other disorders with GERD-like symptoms, such as 
esophageal disorders and functional gastrointestinal disorders, should be considered 
in the differential diagnosis of patients with persistent symptoms (Figure 1).
Figure 1. 
Causes of refractory GERD symptom.
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Additionally, obesity and overeating are other common factors associated with 
PPI failure in patients initially diagnosed with GERD.
4. Diagnosis of refractory GERD symptom
4.1 Symptom evaluation
The first important step is to identify the actual nature of the persisting symp-
toms. It can help a physician to choose the correct equipment for the next step of 
diagnosis. The typical symptoms of GERD are heartburn and regurgitation, which 
can be recognized by the GerdQ questionnaire. It is a revision of the Reflux Disease 
Questionnaire (RDQ ) with positive predictor questions about heartburn and regur-
gitation as well as negative predictors about epigastric pain and nausea. It is reported 
that there is a sensitivity of 65% and specificity of 71% with GerdQ, which is close 
to the efficiency done by the clinical judgment of gastroenterologists [4]. However, 
presenting regurgitation should also be differentiated to gastroparesis or rumination 
syndrome. Except that, the physician should be aware of the proportion of patients 
with the atypical symptoms, such as retrosternal discomfort and pain, cough, asthma, 
hoarseness, throat discomfort, foreign body sensation in throat, globus sensation, 
belching, dysphagia, and epigastric pain and epigastric discomfort.
A recent study shows that there is about half of patients with atypical symptom, 
combined or uncombined with typical symptom [5]. In short, it is essential to figure 
out which symptoms respond and which do not respond to PPI therapy. More detailed 
questioning about symptom often help clarify the cause for a patient’s persistent 
symptoms. Especially, the patients with atypical symptom might have poor response to 
PPI therapy because there are probably other causes or diseases that overlapped GERD.
4.2 Endoscopy
Upper endoscopy should be taken principally to exclude non-reflux esophageal 
disorders and other gastric diseases and to check whether erosive esophagitis exists, 
which can provide evidence of ongoing acid reflux. However, endoscopy is of 
limited value for diagnosis of refractory GERD symptom. It is because that most 
patients have normal endoscopy. The potential reasons are that most patients with 
refractory GERD symptom have other esophageal motility problem; they have non-
erosive reflux disease (NERD); or PPIs they taken has healed the mucosal injury.
4.3 Esophageal manometry
All patients with refractory GERD symptom are strongly recommended to 
undergo esophageal manometry. The purpose mainly is to find esophageal motor 
disorders, for example, achalasia, weak peristalsis, hypertensive esophageal dys-
motility, diffuse esophageal spasm (DES), hiatus hernias (HH), high UES pressure, 
and abnormal lower esophageal sphincter (LES) pressure. Secondly, but more 
important, esophageal manometry is applied for identifying the accurate location 
of LES in order to place reflux monitoring pH sensors.
4.4 Ambulatory monitoring for reflux
There are two methods for esophageal reflux monitoring, called as On-PPI and 
Off-PPI. In off-PPI (7 days after cessation of PPI), the presence of abnormal acid 
reflux and/or positive symptom-reflux relationship can be confirmed. The relevant 
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parameter to be observed is esophageal acid exposure, which is the proportion of time 
(in minutes or percentage of time) spent below pH 4, as well as correlation between 
symptoms and reflux events (symptom index (SI) and/or symptom association prob-
ability (SAP)). Positive symptom association with normal esophageal acid exposure is 
considered hypersensitive esophagus (HE), reflecting an underlying visceral hyper-
sensitivity. For on-PPI reflux monitoring, impedance-pH monitoring should reason-
ably be proposed as the preferred investigation. It can detect nonacid reflux during 
the PPI therapy period, which is one of causes for persistent GERD symptom. It also 
can figure out whether acid reflux is controlled or not by the treatment (Table 1).
4.5 Assessment and evaluation for psychological status
Psychological disorders such as hysteria, anxiety, and distress should also be 
evaluated in patients with refractory symptoms. Weak correlation of symptoms with 
acid reflux events might indicate a high level of anxiety and hysteria as compared 
with patients who demonstrate a close correlation between symptoms and acid 
reflux event [6]. Anxiety and depression have been shown to increase reflux symp-
toms reported in population-based studies. A study has reported that patients who 
did not respond to PPI treatment were suffered from more psychosocial problem [7].
5. Management of refractory GERD symptom
5.1 Lifestyle modifications
Weight loss, head of bed elevation, and avoiding late-night meals, which have been 
shown as effective interventions for GERD, have not been demonstrated yet equally 
useful in patients with refractory reflux symptoms. The value of lifestyle modifications 
in patients with refractory symptoms lies in avoidance of specific lifestyle activities that 
have been identified by patients or physicians to trigger symptoms. A low-bulk and 
low-fat diet along with small but more frequent meals should surely be recommended.
5.2 Medicine
Increasing the PPI dose or to change to an alternative PPI improved the symptom 
in some patients [8]. However, this dosing strategy should be used for a short time 
period (2–3 months) and should be tapered if it does not result in improvement of 
symptoms. The addition of an H2RA at bedtime was shown to significantly reduce 
the duration of nocturnal acid breakthrough (NAB) pain modulators. Transient 
lower esophageal sphincter relaxation (TLESR) reducers can be considered for 
patients with abnormal frequency of nonacid reflux. The drugs that can reduce 
the number of reflux events regardless of their acidity are theoretically desirable 
Nonerosive reflux disease (NERD) No mucosal break
Normal esophageal acid exposure
Hypersensitive esophagus (HE) No mucosal break
Normal esophageal acid exposure SI > 50%, SAP > 95%
Functional heartburn (FH) Heartburn refractory to PPIs,
no mucosal break,
normal esophageal acid exposure SI < 50%, SAP < 95%
Table 1. 
Diagnosis based on endoscopy, esophageal manometry, and ambulatory monitoring for reflux.
5Refractory Gastroesophageal Reflux Disease (GERD) Symptoms
DOI: http://dx.doi.org/10.5772/intechopen.80792
because of the potential for weakly acidic or bile reflux to cause symptoms. 
Nevertheless, high-quality controlled trials are needed to demonstrate its efficacy in 
patients with refractory symptoms.
Visceral pain modulator therapy has been another option for patients with an 
acid-hypersensitive esophagus or functional heartburn. A randomized, placebo-con-
trolled trial has demonstrated citalopram 20 mg/day to be of symptomatic benefit in 
patients with acid-hypersensitive esophagus and refractory GERD symptoms [9].
5.3 Endoscopic therapy
Stretta procedure and EsophyX transoral incisionless fundoplication are two 
antireflux endoscopic devices which are clinically available. The Stretta procedure 
showed clinical improvement of esophageal symptoms and a decrease in PPI use but 
no significant effect on esophageal acid exposure [10]. EsophyX offers a less inva-
sive alternative to laparoscopic fundoplication for PPI-dependent GERD patients, 
which still needs further studies to demonstrate its efficiency.
5.4 Antireflux surgery
Comparing with patients with adequate PPI symptom control, antireflux 
surgery might have a less favorable clinical outcome for the patients with refractory 
GERD symptom. Normal acid exposure and the presence of atypical reflux symp-
toms and persisting symptoms despite PPI therapy are predictors of a poor postop-
erative outcome. It is important to confirm pathological reflux before considering 
antireflux surgery if there is no proven esophagitis. Summarily, surgery can be a 
valuable option in patients with typical reflux symptoms with inadequate response 
to PPIs, provided abnormal esophageal acid exposure and/or positive symptom 
association analysis in off-PPI test [11].
5.5 Psychological treatment
According to a recent research, perceptions of reflux symptoms are associated 
with psychosocial distress in these patients with refractory GERD symptom who 
Figure 2. 
Diagnostic and treatment algorithm for patients with refractory GERD symptom.
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have normal impedance-pH results. Furthermore, patient-reported symptom sever-
ity is associated with physiological differences, as opposed to psychosocial factors 
[11]. In these patients with psychological disorders, treatment-targeted psychoso-
cial abnormality may improve patient response to PPI therapy [2]. Psychological 
treatment should be a potential consideration in the case of the patients without 
other identifiable causes. In many clinical experiences, psychological disorders may 
be an underlying etiology in many patients with refractory symptoms (Figure 2).
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